YERVOY®

(ipilimumab)

Patient Card

This Patient Card fulfills the conditions of the marketing authorisation and has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

Date of MHRA Approval: 20 Jun 2025
Local Approval Number: 731-GB-2500001
Date of Preparation: May 2025

Bristol Myers Squibb®

IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY (ipilimumab) alone.

If you have any signs or symptoms, tell your doctor right away.

POSSIBLE SIDE EFFECTS

Bowel and stomach	Diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools, more frequent bowel movements than usual, pain or tenderness in your stomach or abdomen area, nausea or vomiting
Eye	Redness in the eye, pain in the eye, vision problems or blurry vision
Hormone glands	Rapid heartbeat, increased sweating, weight gain or loss, feeling cold, hair loss, constipation, your voice gets deeper, fever, tiredness, headache, dizziness or fainting, feeling more hungry or thirsty than usual, needing to urinate more often, or behavioural changes (e.g. less sex drive, being irritable or forgetful)
Liver	Eye or skin yellowing (jaundice), pain on the right side of your stomach area, dark urine, or bleeding
Lungs	Shortness of breath, cough or chest pain
Nerves	Muscle weakness, numbness or tingling in legs, arms or face, dizziness, loss of consciousness or difficulty waking up
Skin	Skin rash with or without itching, dry skin, blisters and/or peeling of the skin, mouth sores, swelling of the face or lymph glands

Other important side effects:

Severe infusion reactions:

- Reactions to infusing ipilimumab into the bloodstream might occur, usually during or within 24 hours of receiving a dose.
- Tell your doctor or nurse right away if you get these symptoms during an infusion of ipilimumab: chills or shaking, itching or rash, flushing, difficulty breathing, dizziness, fever, and feeling like passing out.

IMPORTANT

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- **DO NOT** try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, read the ipilimumab Package Leaflet at www.medicines.org.uk/emc or contact Medical Information on 0800 731 1736 or medical.information@bms.com.

IMPORTANT Information for Healthcare Professionals

- This patient is treated with ipilimumab monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the ipilimumab Summary of Product Characteristics (SmPC) at www.medicines.org.uk/emc or contact Medical Information on 0800 731 1736 or medical.information@bms.com for more information.

The healthcare professional treating this patient with ipilimumab should complete the 'My Doctor's Contact Information' section of this Patient Card.

My Doctor's Contact Information

(who prescribed ipilimumab)

Name of Doctor: _____

Office Phone: _____

After-Hours Phone: _____

My Contact Information

My Name and Phone: _____

Caregiver Name and Phone (in case of emergency):

_____

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com. By reporting side effects, you can help provide more information on the safety of this medicine.

© 2025 Bristol-Myers Squibb Company.
Yervoy® is a trademark of Bristol-Myers Squibb Company.